High circulating VEGF levels are associated with decreased survival in patients with melanoma treated with either high-dose IL-2 or ipilimumab, thus, suggesting that soluble VEGF can serve as a biomarker of clinical outcome and a potential target to reverse the immunosuppressive tumor microenvironment (TME) (7, 8). The gene discussed is VEGFA; the disease is melanoma.